Status:
COMPLETED
Efficacy and Safety of the Rivastigmine Transdermal Patch in Patients With Probable Alzheimer's Disease
Lead Sponsor:
Novartis Pharmaceuticals
Conditions:
Alzheimer's Disease
Dementia, Alzheimer Type
Eligibility:
All Genders
50-85 years
Phase:
PHASE3
Brief Summary
The goal of this research study is to evaluate the safety and efficacy of the rivastigmine transdermal patch in patients with probable Alzheimer's Disease.
Eligibility Criteria
Inclusion
- Diagnosis of dementia of the Alzheimer's type
- Males, and females who are surgically sterile or one year postmenopausal
- A primary caregiver willing to accept responsibility for supervising the treatment
Exclusion
- Any condition (other than Alzheimer's) that could explain patient's dementia
- An advanced, severe or unstable disease that may put the patient at special risk
- Current diagnosis of active, uncontrolled seizure disorder or unstable cardiovascular disease
Key Trial Info
Start Date :
November 1 2003
Trial Type :
INTERVENTIONAL
End Date :
January 1 2006
Estimated Enrollment :
1040 Patients enrolled
Trial Details
Trial ID
NCT00099242
Start Date
November 1 2003
End Date
January 1 2006
Last Update
October 13 2017
Active Locations (75)
Enter a location and click search to find clinical trials sorted by distance.
1
Orange, California, United States, 92868-3298
2
San Francisco, California, United States, 94109
3
Boca Raton, Florida, United States, 33486
4
Fort Lauderdale, Florida, United States, 33321